Company profile: SiSaf
1.1 - Company Overview
Company description
- Provider of RNA delivery and therapeutics leveraging proprietary Bio-Courier, a hybrid organic–inorganic platform using bioabsorbable silicon and silicon stabilized hybrid lipid nanoparticles (sshLNP). Pipeline includes siRNA/miRNA therapies for Osteopetrosis Type II (SIS-101-ADO), Achondroplasia (SIS-102-ACH), pancreatic cancer (SIS-401-PACA), targeting genes correlating with cancer progression and mortality (SIS-402-SBC), and Type II Corneal Dystrophy (SIS-201-CD).
Products and services
- Bio-Courier Technology: A hybrid organic–inorganic RNA delivery platform combining lipids with bioabsorbable silicon, featuring silicon-stabilized hybrid lipid nanoparticles (sshLNP) that improve RNA delivery and overcome limitations of other technologies
- SIS-102-ACH: A gene-targeted siRNA therapy for Achondroplasia, engineered to inhibit the FGFR3 gene and delivered via proprietary Bio-Courier RNA delivery technology
- SIS-101-ADO: An siRNA-based therapy targeting autosomal dominant Osteopetrosis Type II, utilizing Bio-Courier technology for RNA delivery in relevant disease contexts
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SiSaf
miDiagnostics
HQ: Belgium
Website
- Description: Provider of next-generation point-of-care diagnostic tests and a silicon nanofluidic platform. Offers disposable tests using drops of blood to detect cells, proteins, nucleic acids and small molecules. Products include a <20 min COVID-19 PCR, a <20 min vaginitis test detecting bacterial vaginosis, vulvovaginal candidiasis and trichomonas vaginalis, a <30 min HSV-1&2 CSF test, and the nanoFluidic Processor (nFP).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full miDiagnostics company profile →
Arcturus Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage mRNA medicines and vaccines, including ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved for use in adults; investigational therapies ARCT-032 and LUNAR-CF for cystic fibrosis and LUNAR-OTC for ornithine transcarbamylase deficiency; and platforms STARR™ mRNA Technology and LUNAR® lipid-mediated delivery for nucleic acid drug delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcturus Therapeutics company profile →
RF Nano
HQ: United States
Website
- Description: Provider of a CMOS-compatible suite of carbon nanotube-based discrete, wafer, and integrated circuit products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RF Nano company profile →
Hybrid Plastics
HQ: United States
Website
- Description: Provider of polyhedral oligomeric silsesquioxane (POSS) materials and chemical additives for commercial production and R&D. Hybrid Plastics manufactures and supplies POSS, nanosilica dispersions, optical hard coatings, flow and dispersion aids, lubricants, and adhesives, enhancing mechanical properties and performance across coatings, plastics, and composites, and operating as a research and development catalyst.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hybrid Plastics company profile →
NIL Technology
HQ: Denmark
Website
- Description: Provider of optical solutions designing, developing, and manufacturing optical elements and components. Services include optical design of modules, meta-optical and diffractive elements; metalens prototyping for NIR/SWIR/VIS using electron beam lithography; optical testing in Denmark and Switzerland; micro/nanostructuring and high-volume replication via UV-curable or thermoplastic processes for mass production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NIL Technology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SiSaf
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SiSaf
2.2 - Growth funds investing in similar companies to SiSaf
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SiSaf
4.2 - Public trading comparable groups for SiSaf
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →